Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9571
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKrum, Henryen
dc.contributor.authorLouis, William Jen
dc.contributor.authorBrown, Douglas Jen
dc.contributor.authorHowes, L Gen
dc.date.accessioned2015-05-15T22:43:11Z
dc.date.available2015-05-15T22:43:11Z
dc.date.issued1992-04-01en
dc.identifier.citationClinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society; 2(2): 83-8en
dc.identifier.govdoc1353386en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9571en
dc.description.abstractThe ability of the alpha-1 adrenoceptor antagonist, prazosin, to reduce the severity and duration of episodes of autonomic dysreflexia was studied in cervical and high thoracic spinal cord injury patients with documented episodes of autonomic dysreflexia. Sixteen patients participated in a double blind parallel group study comparing prazosin 3 mg b.d. with placebo given for 2 weeks. Both groups were matched for age, sex and baseline severity of autonomic dysreflexia episodes. Prazosin was well tolerated and did not produce a significant lowering of resting blood pressure. Compared to baseline measurements, patients allocated to prazosin therapy were found to have fewer severe episodes of autonomic dysreflexia and during these episodes to have significant reductions in average rise in systolic and diastolic blood pressure, symptom duration and requirement for acute antihypertensive medication. The severity of headache during individual autonomic dysreflexia episodes was also diminished with prazosin therapy. No symptom parameter was significantly altered by placebo therapy. It is concluded that prazosin is superior to placebo in the prophylactic management of autonomic dysreflexia and that these findings are consistent with suggestions that alpha-1 adrenoceptors play an important role in the pathogenesis of this syndrome.en
dc.language.isoenen
dc.subject.otherAdolescenten
dc.subject.otherAdrenergic alpha-Antagonists.therapeutic useen
dc.subject.otherAdulten
dc.subject.otherAutonomic Nervous System Diseases.etiology.prevention & controlen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherDouble-Blind Methoden
dc.subject.otherHumansen
dc.subject.otherMiddle Ageden
dc.subject.otherPrazosin.therapeutic useen
dc.subject.otherReflex.drug effectsen
dc.subject.otherSpinal Cord Injuries.complicationsen
dc.titleA study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical autonomic research : official journal of the Clinical Autonomic Research Societyen
dc.identifier.affiliationDepartment of Clinical Pharmacology, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages83-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1353386en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.